Overview

Probiotics in Advanced Urothelial Carcinoma

Status:
RECRUITING

Trial end date:
2028-01-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, controlled phase II Study of evaluating the efficacy and safety of immunotherapy combined with probiotics compound (Biolosion) in patients with advanced urothelial carcinoma.

Phase:

PHASE2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

130-nm albumin-bound paclitaxel
Cisplatin
disitamab vedotin
enfortumab vedotin
Gemcitabine
pembrolizumab
toripalimab